Moderna, Inc. — Wall Street Analyst Estimates & Price Targets

MRNA

NASDAQHealthcareBiotechnologyCIK 0001682852modernatx.comAbout MRNA

Last close · Oct 16, 2026218.01−18.49 (−7.82%)

Market cap$87.0B

8 firms' latest targets, last 90 days: median $132.50 ($25.00–$245.00), 39% below the last close.

Price and published targets

daily close, 12 months · each dot a target, a firm's latest darker

Each firm's latest target

last 90 days · 8 firms

Date	Firm	Target	Previous	Change	Vs price then	Vs price now
2026-10-15	Goldman Sachs	$137.00	$120.00	▲ 14%	-39%	-37%
2026-09-03	UBS	$81.00	$150.00	▼ 46%	-46%	-63%
2026-08-28	Argus Research	$180.00	—	—	+26%	-17%
2026-08-24	Barclays	$125.00	—	—	-14%	-43%
2026-08-19	RBC Capital	$130.00	$45.00	▲ 189%	-14%	-40%
2026-08-19	Loop Capital Markets	$135.00	—	—	-3%	-38%
2026-08-19	D.A. Davidson	$245.00	—	—	+77%	+12%
2026-07-20	Wolfe Research	$25.00	$17.00	▲ 47%	-60%	-89%

Consensus estimates

revenue and EPS by fiscal year · reported years marked

FY	Revenue	YoY	EPS	YoY	Revenue range	EPS range	Analysts
2023reported	$6.8B	-64%	-$12.33	-161%	est. $6.5B+6%	est. -$13.46	15
2024reported	$3.2B	-53%	-$9.28	—	est. $3.2B+1%	est. -$9.05	17
2025reported	$1.9B	-40%	-$7.26	—	est. $1.9B+2%	est. -$7.84	11
2026	$2.1B	+8%	-$8.31	—	$2.0B–$2.2B	-$10.32–-$7.81	17
2027	$2.4B	+16%	-$4.74	—	$2.0B–$3.0B	-$7.56–-$2.90	16
2028	$3.4B	+41%	-$2.72	—	$2.2B–$7.4B	-$5.35–$0.60	16
2029	$5.6B	+63%	$0.50	—	$4.5B–$7.7B	$0.38–$0.75	14
2030	$7.6B	+36%	$3.42	+582%	$6.2B–$10.4B	$2.60–$5.08	14

A reported year shows the company's figures, with the consensus beside it (revenue against it in %). Reported EPS is GAAP diluted; the analysts' EPS usually leaves items such as stock compensation out, so the two are not like for like. Faded: a year the valuation models do not read — they read the first 3, and a later one only while 10 or more analysts cover every year up to it — or one under 5 analysts.

The analysts at a glance

$132.50median target, 39% below the last close

Firms with a target · last 90 days: 8
Lowest – highest target: $25.00 – $245.00
Current grades of 16 firms: positive / neutral / negative: 3 / 8 / 5
Upgrades / downgrades · 12 months: 3 / 2
Consensus revenue growth · next 3 FY: +21% a year

Current grades

each firm's latest · 16 firms

As of	Firm	Grade
2026-10-15	Goldman Sachs	“Neutral”
2026-10-07	Morgan Stanley	“Equal Weight”
2026-09-30	Citigroup	“Sell”
2026-09-03	Rothschild & Co	“Sell”
2026-08-28	Argus Research	“Buy”
2026-08-25	Wolfe Research	“Peer Perform”
2026-08-24	Barclays	“Equal Weight”
2026-08-21	J.P. Morgan	“Underweight”
2026-08-20	UBS	“Neutral”
2026-08-19	William Blair	“Outperform”

6 more

2026-07-07	Bank of America	“Underperform”
2026-07-07	RBC Capital	“Sector Perform”
2026-06-26	Piper Sandler	“Overweight”
2026-05-04	Evercore ISI	“In Line”
2025-11-21	Leerink Partners	“Underperform”
2025-10-20	Needham	“Hold”

Grade changes

last 24 months · 8

Date	Firm	Grade
2026-09-30	Citigroup	“Neutral” → “Sell” downgrade
2026-09-03	Rothschild & Co	“Neutral” → “Sell” downgrade
2026-08-28	Argus Research	“Hold” → “Buy” upgrade
2026-08-25	Wolfe Research	“Underperform” → “Peer Perform” upgrade
2026-08-19	William Blair	“Market Perform” → “Outperform” upgrade
2025-02-18	Barclays	“Overweight” → “Equal Weight” downgrade
2024-12-18	Argus Research	“Buy” → “Hold” downgrade
2024-11-18	HSBC	“Hold” → “Buy” upgrade

33 older than 24 months

2024-08-06	Deutsche Bank	“Sell” → “Hold” upgrade
2024-08-05	RBC Capital	“Outperform” → “Sector Perform” downgrade
2024-02-26	HSBC	“Hold” → “Reduce” downgrade
2024-01-02	Oppenheimer	“Perform” → “Outperform” upgrade
2023-11-03	HSBC	“Reduce” → “Hold” upgrade
2023-11-02	Deutsche Bank	“Hold” → “Sell” downgrade
2023-08-04	TD Cowen	“Outperform” → “Market Perform” downgrade
2023-08-03	Deutsche Bank	“Buy” → “Hold” downgrade
2023-06-26	UBS	“Neutral” → “Buy” upgrade
2023-03-13	TD Cowen	“Market Perform” → “Outperform” upgrade
2023-02-24	Leerink Partners	“Market Perform” → “Underperform” downgrade
2022-12-19	Jefferies	“Hold” → “Buy” upgrade
2022-12-14	Chardan Capital	“Buy” → “Neutral” downgrade
2022-10-21	Leerink Partners	“Underperform” → “Market Perform” upgrade
2022-09-08	Deutsche Bank	“Hold” → “Buy” upgrade
2022-01-26	Deutsche Bank	“Sell” → “Hold” upgrade
2022-01-21	Bank of America	“Underperform” → “Neutral” upgrade
2021-12-07	TD Cowen	“Market Perform” → “Perform” revised
2021-10-15	Piper Sandler	“Neutral” → “Overweight” upgrade
2021-08-06	Oppenheimer	“Outperform” → “Perform” downgrade
2021-08-06	Piper Sandler	“Overweight” → “Neutral” downgrade
2021-02-01	Bank of America	“Neutral” → “Underperform” downgrade
2020-12-16	Morgan Stanley	“Overweight” → “Equal Weight” downgrade
2020-12-16	Jefferies	“Buy” → “Hold” downgrade
2020-12-09	Needham	“Buy” → “Hold” downgrade
2020-11-25	Bank of America	“Buy” → “Neutral” downgrade
2020-11-25	J.P. Morgan	“Overweight” → “Neutral” downgrade
2020-11-25	Leerink Partners	“Market Perform” → “Perform” revised
2020-11-17	BMO Capital	“Outperform” → “Market Perform” downgrade
2020-09-08	Leerink Partners	“Market Perform” → “Underperform” downgrade
2020-07-23	Leerink Partners	“Market Perform” → “Perform” revised
2020-07-20	J.P. Morgan	“Overweight” → “Neutral” downgrade
2020-03-05	Bank of America	“Buy” → “Neutral” downgrade

Targets, grades and estimates are quoted from third parties (via Financial Modeling Prep) and are theirs, not ours; each target links to the report it was published in. A firm counts once, at its latest target or grade.